Article

Funding focuses on blinding eye disease

Blinding eye diseases will be the focus of $350,000 in research funded by Research to Prevent Blindness at the John A. Moran Eye Center of the University of Utah, Salt Lake City, and in the Department of Ophthalmology at the University of California, San Diego, School of Medicine.

Salt Lake City and San Diego-Blinding eye diseases will be the focus of $350,000 in research funded by Research to Prevent Blindness (RPB) at the John A. Moran Eye Center (JMEC) of the University of Utah, Salt Lake City, and in the department of ophthalmology at the University of California, San Diego (UCSD), School of Medicine.

At the JMEC, Gregory Hageman, PhD, has received a $150,000 Senior Scientific Investigator Award. Dr. Hageman is the John A. Moran Presidential Professor of Ophthalmology and Visual Sciences and the director of the Moran Center for Translational Medicine.

Also, JMEC’s department of ophthalmology and visual sciences has received $100,000 for research to be directed by Randall J. Olson, MD, chairman of the department and chief executive officer of the JMEC.

“We are grateful to RPB for their charitable gifts and continual support of our research,” Dr. Olson said. “The research efforts at the [JMEC] are moving forward at a rapid pace, and these gifts will further the studies that will lead to treatments and cures for devastating eye diseases.”

To date, RPB has awarded grants totaling $4.8 million to the University of Utah.

UCSD has received a $100,000 grant for research to be directed by Robert N. Weinreb, MD, chairman of the ophthalmology department and director of the Shiley Eye Center.

“These funds are particularly invaluable for enhancing our ability to conduct the most impactful vision research,” he said. “They will facilitate existing research, support cross-disciplinary investigative programs, and assist in the translation of our research to prevent and cure blindness.”

The institution has received more than $3 million in grants from RPB since 1984, supporting research in glaucoma as well as cornea and retinal diseases.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.